Tumor angiogenesis is one of the main pathways targeted to treat cancer. Bevacizumab added survival benefit when combined with platinum-based chemotherapy in NSCLC. Recently, Phase III trials showed survival benefit when anti-angiogenic drugs are added to docetaxel as second-line treatment for NSCLC. These anti-angiogenic agents include nintedanib and ramucirumab, a tyrosine-kinase inhibitor and a monoclonal antibody, respectively, which target receptors involved in angiogenesis. These studies have some similarities and differences. We propose a new algorithm for treatment sequences in performance status 0-1 patients with non-oncogene-addicted NSCLC type adenocarcinoma. Indeed clearer scientific evidences are available for this subgroup of patients.
Bronte, G., Passiglia, F., Galvano, A., Russo, A. (2016). Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard?. EXPERT OPINION ON BIOLOGICAL THERAPY, 16(1), 1-5 [10.1517/14712598.2015.1075000].
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard?
Bronte, Giuseppe;Passiglia, Francesco;Galvano, Antonio;Russo, Antonio
2016-01-01
Abstract
Tumor angiogenesis is one of the main pathways targeted to treat cancer. Bevacizumab added survival benefit when combined with platinum-based chemotherapy in NSCLC. Recently, Phase III trials showed survival benefit when anti-angiogenic drugs are added to docetaxel as second-line treatment for NSCLC. These anti-angiogenic agents include nintedanib and ramucirumab, a tyrosine-kinase inhibitor and a monoclonal antibody, respectively, which target receptors involved in angiogenesis. These studies have some similarities and differences. We propose a new algorithm for treatment sequences in performance status 0-1 patients with non-oncogene-addicted NSCLC type adenocarcinoma. Indeed clearer scientific evidences are available for this subgroup of patients.File | Dimensione | Formato | |
---|---|---|---|
Expert Opinion on Biological Therapy Bronte Passiglia 2016.pdf
Solo gestori archvio
Dimensione
719.59 kB
Formato
Adobe PDF
|
719.59 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.